1. Stabilized and Destabilized α-Helices

α-Helices have been found to be the secondary structure about 40% of all residues in natural proteins adopt [1], and they are widely used as fundamental recognition elements in many naturally occurring protein complexes, such as Bcl-2/Bak, MDM2/p53, calmodulin/smooth-muscle-myosin-light-chain kinase, Vav/DH domain, and CREB/CBP [2–5].

A typical α-helix completes one rotation with 3.6 amino acid residues, in which each has backbone dihedral angles of $\Psi = -41^\circ$ and $\Phi = -62^\circ$ [6]. This results in the helix having a rise of 1.5 Å/residue or 5.4 Å/turn [7]. Therefore, the side chain of a certain residue at the position $i$ projects from the same face with the side chains at the $i + 4$ and the $i + 7$ positions in the sequence (Figure 1). The backbone of the α-helix is primarily stabilized by hydrogen bonds between the carbonyl of residues $i$ and the carboxamide of residues $i + 4$, which all point in the same direction [6]. Because the hydrogen bonding sites on the first and last turns of an α-helix are unfulfilled, a macrodipole is produced [8, 9]. The positive end of the dipole is centered at the N-terminus and the negative at the C-terminus. The total dipole is augmented if the peptide existed in conditions where both the termini are ionized.

It can be imagined that isolated helical peptides would be ideal inhibitors of macromolecular interactions [10]. However, because many peptides, especially those with less than ten residues, rarely contain sizable degrees of helicity in isolation, much work has been done toward the goal of helix induction and stabilization [11]. The goal of this paper is to highlight the chemical strategies employed to stabilize protein secondary structures and the applications of the constrained peptides in regulating protein-protein interactions.

1.1. Covalent Stabilization. The formation of covalent linkages between adjacent residues in peptides has been shown to impart stabilization to the helical form of the peptide. Disulfide bonds, lactam linkages, hydrazones, and carbon-carbon bonds have all been used to link $i$ to $i + 4$ or $i + 7$ residues in a peptide and promote helicity (Figure 2). The particularly noteworthy examples include the creative approach Jackson et al. have conducted, using a redox-triggered disulfide bond to influence the helix-coil transition [12] and the medicinally useful stabilization techniques of lactam tethers developed by Taylor et al. [13, 14]. Both disulfide bonds and lactam linkages could induce the conserved pentapeptide motif (LXXLL) to adopt an α-helical structure [15, 16]. Fairlie and coworkers have shown their efforts on downsizing protein to short synthetic peptides with strategically lactam bridged α-helical structures that are stable in water. Their work covered viral (respiratory syncytial virus (RSV) F protein, HIV rev), bacterial (Streptococcus pneumonia competence stimulating peptide (CSP)), and human (nociceptin) proteins [17, 18]. Flint et al. have shown that linkage of a diazobenzene unit through two cysteine thiols can be used to both stabilize and destabilize the helical form of a peptide under photocontrol [19]. Linkage of the photoaddressable unit
azobenzene (AZO) to the \(i\) and \(i + 4\) residues of the helix allows stabilization of the helix in the cis-form, whilst linkage between the \(i\) and \(i + 11\) results in destabilization on trans/cis-isomerization (Figure 3). The results are attributed to the shorter distance between the aromatic units of the cis-isomer as compared to the trans isomer.

Blackwell and Grubbs have demonstrated that linkage through olefin metathesis of two O-allyl serines at \(i\) and \(i + 4\) positions can facilitate the transition from an \(\alpha\)-helix to a \(3_{10}\) helix in nonpolar solvents [20]. These preliminary results offered great promise due to the advent of water-soluble metathesis catalysts and ready functionalization of serine residues. In a more recent example, Schafmeister et al. have elaborated upon this work to show that enhanced and compromised helix stability can be conferred upon the C-terminal peptide of RNase A via incorporation and subsequent metathesis of \(\alpha,\alpha\)-disubstituted amino acids [21]. Linkage of \(i\) and \(i + 7\) residues with an 11-carbon linker increased the helicity from 40% to 66%, whereas linkage with a 9 or 10 carbon linker decreased helicity by 21% and 12%, respectively. Linkage with a 12-carbon linker conferred only a small increase in helicity. Trypsin proteolysis experiments demonstrated that the peptides modified at the \(i\) and \(i + 7\) residues with an 11-carbon linker had increased proteolytic stability as the rate of cleavage was decreased 41-fold upon olefin metathesis. The Verdine group further elaborated this “peptide stapling” strategy in which an all-hydrocarbon cross-link is generated within natural peptides by ruthenium-catalyzed olefin metathesis of inserted \(\alpha,\alpha\)-disubstituted nonproteogenic amino acids bearing olefinic side chains, and use it in some antitumor fields [22]. They utilized hydrocarbon-stapled helices to target the intracellular protein-protein interaction between the activation domain of p53 and its negative regulator HDM2, resulting in upregulated expression of p53 and activation of apoptotic signal [23]. This group also found that hydrocarbon-stapled helices could inhibit coactivator mastermind-like (MAML) protein 1 binding to transcription factors CSL-Notch (ICN), and suppress the expression of Notch-mediated genes [24].

Patgiri and coworkers have developed another strategy for the stabilization of \(\alpha\)-helices involving replacement of one of the main chain intramolecular hydrogen bonds with a covalent linkage [25]. The transition theory suggests that energetically demanding organization of three consecutive amino acids into the helical orientation limits the stability of short \(\alpha\)-helices [26, 27]. Replacement of the N-terminal backbone hydrogen bond between the \(i\) and \(i + 4\) residues with a covalent carbon bond through a ring-closing metathesis reaction drives the formation of an \(\alpha\)-turn [28]. The hydrogen bond surrogate (HBS) strategy induces
preorganized \( \alpha \)-turns to overcome the intrinsic nucleation barrier and initiate helix formation [29]. HBS helices have been demonstrated to target with high affinity in cell-free and cell culture assays [30, 31].

1.2. Noncovalent Stabilization. Stabilization of \( \alpha \)-helical structure has also been achieved using noncovalent interactions between appropriately spaced residues in a peptide chain. Notably metal-ligand interactions, designed host-guest interactions, salt bridges, cation-\( \pi \) interactions, and \( \pi-\pi \) stacking have resulted in helix stabilization (Figure 4). A report by Kelso and coworkers has shown that such metal-ligand interactions can be used to stabilize the helical form of even the shortest peptides [32]. AcHAAAHNH\( _2 \) ligates to the vacant \( \text{cis} \)-coordination sites of Pd(en)(NO\( _3 \))\( _2 \) and confers \( \alpha \)-helical stability as shown by 2D ROESY in DMF and water. This strategy has recently been extended further to design 5, 10, and 15 residue nonhelical peptides DMF and water [34]. Phosphine-ruthenium coordination has also served to stabilize helical conformations in a similar manner. Shinkai et al. used a technique developed by Ruan et al. to bridge the backbone on one face of a helix and stabilized the helical structure of the S-peptide of ribonuclease S to effectively turn on and off enzymatic activities in the presence of various metals [1, 35, 36]. Ghadiri et al. and Lieberman and Sasaki both designed helical bundles that were formed in the presence of coordinating metals [37–39]. Another example has been reported by Huang and coworkers who employ an amidolinked BipyRu\( _{\text{III}} \)\( \text{(Bipy)}_2 \) which on oxidation to Ru\( _{\text{III}} \) causes increased polarization of the amide causing a transition from a random coil to \( \alpha \)-helical conformation [40]. Cline and coworkers utilize model \( \alpha \)-helical peptides containing two cysteine residues in various sequential arrangements and spatial locations to study the structural effects of arsenic binding. With \( i \) and \( i + 1, i + 2, \) or \( i + 3 \) arrangements, CD spectroscopy shows that As(III) coordination caused helical destabilization when Cys residues are located at central or C-terminal regions of the helix. In contrast, helical stabilization was observed for peptides containing \( i, i + 1 \), and \( i + 2 \) Cys residues [41].

Host-guest interactions have recently been employed to develop conformationally sensitive sensors by Matsumura and coworkers [42]. The peptide EK6R employing a \( \beta \)-cyclodextrin (CD) and dansyl group (Dns) at the eighth and fifteenth positions was shown to exhibit enhanced helicity as a result of the formation of an inclusion complex between the CD and hydrophobic Dns group. Competition for the CD cavity with various guests causes a decrease in Dns fluorescence resulting from the transition to aqueous media. GdnHCl-induced denaturation of the peptide demonstrated the importance of the correct presentation of CD and Dns along the surface of the peptide scaffold in order for effective sensing. Voyer and Guérin demonstrated that peptides incorporating a crown ether-containing amino acid could stabilize a helix by binding to another residue with an ammominium functionality [43]. Wilson et al. reported cyclodextrin dimmers as the helical template. The chelated binding of cyclodextrin-based receptor with the two hydrophobic side chains in the \( i, i + 11 \) positions of an oligopeptide was shown to be able to induce helicity in the peptide. CD experiments revealed that a dimeric \( \beta \)-cyclodextrin receptor synthesized from a \([1, 1'-\text{biphenyl}]-4.4'-\text{dithiol}\) core demonstrated an ability to fold a designed peptide bearing the artificial amino acid L-p-t-butylphenylalanine in the \( i, i + 11 \) positions [44].

The role of cation-\( \pi \) interaction in protein secondary structure stabilization has not been thoroughly studied until lately. Some early studies have suggested that cation-\( \pi \) interactions contribute more in stabilization than salt bridges on a solvent-exposed protein surface [45]. Kallenback et al. demonstrated that the Trp-Arg \( (i, i + 4) \) pair stabilized the \( \alpha \)-helical conformation with a quantified stabilization energy of \(-0.4\) kcal/mol [46, 47]. Gallivan and Dougherty conducted computational simulation to provide energetic evaluations to all potential cation-\( \pi \) interactions in a protein [48]. It was shown that the side chain of Arg is more likely than that

![Figure 3: Structure of azobenzene reagents and the primary sequence of the cross-linked peptide.](image-url)
of Lys to be in a cation-π interaction. However, Tsou and coworkers reported the stabilization of α-helices obtained by Phe- and Lys cation-π interaction in water with a stabilizing energy of ~0.4 kcal/mol, which is comparable to the Arg-Trp pair [49]. Rather than a “face to face” orientation, the Arg-Trp pair takes the Phe-Lys pair adopt through a “point to face” mode due to the lack of delocalization of the positive charge on the side chain. Three different arm lengths of the ammonium-containing side chains were screened (Lys, ornithine, and diaminobutanoic acid residues). Orn (i) was identified to have the optimal length in building interaction with Phe at the i + 4 position, indicating that the subtle factors, such as side chain length, influence the interaction energies in designed systems.

A logical progression from the stabilization of peptides through intramolecular interactions is the stabilization of peptides through intermolecular interactions (Figure 5). Albert et al. have shown in several studies that the α-helical form of a peptide can be stabilized by the interaction of bis-guanidinium receptors with aspartate residues at the i and i + 4 residues on a peptide [50]. An alternative approach to stabilize a helix was accomplished through the use of π-π stacking interactions [51]. Similarly Tabet and coworkers have shown that naturally occurring spermine can stabilize the α-helical form of a peptide by binding to aspartate residues at the i, i+4, i+7, and i+11 residues [52]. This effect was capitalized on by Hamachi et al. to stabilize ribonuclease S-peptide [53]. Related studies in the Hamilton laboratory have shown that binding of the tetraguanidinium receptor 1 to an appropriately designed tetra-aspartate peptide at i, i + 3, i + 6, and i + 9 positions can result in a stabilization of the α-helical form of the peptide [54, 55]. In an elegant extension of this work, the design of a “molecular hinge” was exploited (Figure 5) [56]. The target peptides incorporate four aspartate groups, each flanked above or below by aromatic residues on the helix surface. In this way, the tetraguanidinium receptor 1 can make both hydrogen bonds and cation-π interactions with side chain groups on the peptide. It has been shown that the peptide receptor 1 not only binds with high affinity but also acts to strongly stabilize the helix conformation of the peptide.

The strategy to use a Ca-tetrasubstituted amino acid to constrain peptide to form helices was employed by several groups recently. Schievano et al. reported that Aib-rich (Figure 6) peptides containing lactam-bridged side chain adopted a right-handed 3₁₀ helix conformation [57]. The 3₁₀ helices are another important class of secondary structural element in proteins. Traditionally, it is a challenge to identify 3₁₀ conformations because of their similar spectroscopic characteristics to α-helices. The backbone dihedral angles φ and Ψ of the two helices differ only by 6° and 12°, respectively [58]. Peggion and coworkers managed to analyze the constrained peptide by conducting a detailed CD and NMR analysis followed by a NOE-distance-based structure ensemble calculations using the XPLOR simulated annealing protocol. They used an i, i + 3 lactam bridge, which was both 3₁₀ helix stabilizing and α-helix destabilizing, to assure the constrained peptide predominantly fold into the 3₁₀ helix conformation. It was found the Aib-rich peptide oligomers tend to form 3₁₀ helix upon chain elongation. The presence of the 3₁₀ helices was further supported by the temperature coefficients of the –NH proton chemical shifts, which are in the range usually observed in an H-bonded structure. Similarly, the employment of (R)-c₃Val(1-amino-2,2-dimethylcyclopropane-1-carboxylic acid), an extremely strained analogue of the previously used (aMe)Val (Figure 6), has been reported [58, 59]. It was shown that c₃Val was a good β-bend and helix former though not as efficient as (aMe)Val. ¹H-NMR experiments showed in CDCl₃ solution of the c₃Val constrained peptide that the N₉₃ H to N₇ H protons are intramolecularly H-bonded, suggesting that the secondary structure the peptide adopted in CDCl₃ is a 3₁₀ helix. The conclusion was further confirmed by the X-ray crystal structure.

1.3. Other Stabilization Strategies. Another noticeable field of helical stabilization using constrained peptide was achieved with β-peptides by groups of Seebach, Gellman, and...
DeGrado [60, 61]. The design of \( \beta \)-peptides that adopt helical conformations in organic solvent and water has been observed with conformationally restricted cyclic amino acids or side chain electrostatic interactions. \( \beta \)-peptide foldamers are composed of \( \beta \)-amino acid residues and are capable of adopting helical structures [62–64]. Foldamers are artificial nonpeptidic oligomers displaying protein-like function to target receptors whilst resisting proteolytic degradation [65]. Recent work has shown that heterogeneous backbone foldamers compared to homogeneous backbones ones have more benefits in designing stable conformation [66]. The Schepartz, Seebach, and Gellman groups have demonstrated the potentials of \( \beta \)-peptide foldamers to target proteins involved in transcription [65, 66, 67].

Last, synthetic agents have been shown to act as nucleators of helix formation. By providing rigidly constrained, appropriately placed hydrogen bonds to one end of a peptide, Kemp et al. [69, 70], Austin et al. [71], and Kazmierski et al. [72] have all provided means for nucleation of helicity.

### 2. Stabilized and Destabilized \( \beta \)-Sheets and \( \beta \)-Turns

The mimicry of \( \beta \)-turns is a fertile area of research. Notable examples include the use of \( meta \)-amino-benzoic acid by DeGrado, the 9-membered macrocycles of Olsen and Kahn, 13-membered Ala-Gly turn analogues, and the macrocyclic \( \beta \)-turn mimetic of Ellman et al. [73, 74]. Burgess has reported several solid-phase syntheses of ring-fused \( C^{10} \) motifs and is now using these mimetics to function as synthetic antibody models [75]. Cochran and coworkers have recently outlined a minimal peptide scaffold for \( \beta \)-turn display employing disulphide-cyclized \( \beta \)-hairpins. They found that tryptophan in the 3 positions of a constrained \( \beta \)-hairpin of the form CXC\( \beta \) was found to confer stability to the turn conformation. Because the scaffold is composed of natural amino acids, it is amenable to the development of peptide libraries on phage having limited conformational diversity [76, 77].

Kelly et al. have developed \( \beta \)-turn mimetics-based dibenzofuran scaffold that induces \( \beta \)-hairpin formation in small peptides by replacing the \( i + 1 \) and \( i + 2 \) residues of a \( \beta \)-turn (Figure 7) [78–81]. It was shown that the incorporation of X into a WW domain of PIN1, a mitosis cell cycle regulator, can result in increased stability of the resultant miniprotein relative to the wild-type protein [82, 83]. The WW domain was named after two conserved tryptophan residues found in over 200 members in this protein family. This domain is readily accessible by solid-phase peptide synthesis (SPPS). Synthesized proteins exhibit cooperative folding transitions that facilitate kinetic and thermodynamic analysis. Such miniproteins represent useful probes of the role of the loop region with regard to the folding of \( \beta \)-sheets and the role of loops in general. The WW domain of PIN1 folds into a three-strand antiparallel \( \beta \)-sheet with two loops, which contains six and four residues, respectively. As loop 1 is solvent exposed and therefore not involved in other interactions, it was decided to incorporate a turn mimic at this site. The protein exhibits what appears to be an unusual type II \( \beta \)-turn from S16 to S18 centered around R17 (\( i + 1 \)) and S18 (\( i + 2 \)). To test if this was important or not, S18 and S19 were substituted with known \( \beta \)-turn mimics dPro-Gly and Asn-Gly and the resultant mutants found to have little difference.
in structural stability. Incorporation of the dibenzofuran mutant resulted in a protein that was thermally less stable by 10°C. However, it was shown to be slightly more stable to chaotropic denaturation by 0.5 kcal/mol. Subsequent work has shown that acidic side groups tethered to the back side of the dibenzofuran allow incorporation of the turn mimetic with an increased stability comparable to that of the wild-type protein resulting from the improved solvation of the polypeptide chain is projected. The resulting antiparallel orientation of the two peptide chains is conducive to β-sheet formation. Likewise, 1,1′-bis-carboxy ferrocenes allow the projection of peptide side arms in a parallel orientation.

### 3. Regulating Protein–Protein Interactions with Constrained Peptides

Incorporation of iminodiacetic acid-appended amino acid (Idd) residues into the S-peptide of RNase S′ allows regulation of the stability of the complex it formed with the S-protein and thus regulation of RNase S′ activity as shown by Hamachi et al. [36]. This elegant design involves installments of two Idd residues, which are strong chelators for transition metal cations in aqueous solution. Due to the hydrophilicity characteristics of the acid side chains, the peptide was oriented with the metal binding site exposed to the solvent side. It is shown that doubly replaced Idd in the S-peptide at the i and i + 3 sites cooperatively binds a Cu²⁺ cation then results in an increase of the helix content (Figure 8), which is called single-mode binding. This peptidocopper complex is able to pick up another Cu²⁺ if the concentration of Cu²⁺ is high enough to form a dual-mode complex. The single mode with stoichiometry of 2:1 binding enhanced the activity of A6/E9Ida-Rnase S′, while the dual mode with 2:2 stoichiometry suppressed it. The opposite effects from different binding modes provided a switch to control the enzyme activities by addition of chemical reagents. Thus, it has to be a very promising frontier work of molecular level engineering.

C5a is believed to be a pathogenic factor in a range of immunoinflammatory diseases including sepsis and may therefore serve as a useful target for anti-inflammatory agents. Finch and coworkers produced cyclic peptides that mimic the structure of active peptide inhibitors of the C5a receptor. These were derived from peptide fragments containing the binding region obtained by site-directed mutation of C5a [101]. The most potent of these inhibitors
bound to the receptor with IC\textsubscript{50} = 0.3 M as measured in a competition assay using \textsuperscript{125}I-labeled C5a. The cyclic peptide displayed antagonist potency in the presence of 100 nM C5a with IC\textsubscript{50} = 20 nM as measured by myeloperoxidase release from cytochalasin B stimulated human polymorphonuclear cells. Compared to control animals, anesthetized rats dosed intravenously with X when subjected to either C5a or lipopolysaccharide (which stimulates an increase in endogenous C5a) displayed significantly reduced neutropenia (decrease in circulating PMNs) and blocked the elevation of serum TNF-\(\alpha\) and IL6, two proinflammatory cytokines [102].

A delightful example employing constrained peptides that act as inhibitors of protein-protein interactions has been described in the work reported by Garcia-Echeverria et al. [103]. Antibodies were used to identify the binding region between p53 and human double minute 2 (HDM2). Synthetic peptides from the N-terminus of p53 were then used to probe further the binding region on HDM2. A hexapeptide comprising residues 18–23 of p53 was identified as the minimum binding epitope for HDM2 recognition with an IC\textsubscript{50} = 700 \(\mu\)M. However, a peptide comprising 12 residues from p53 displayed a more respectable IC\textsubscript{50} = 8.7 \(\mu\)M and was used as a starting point for further studies. Phage display identified a 12-mer with 28-fold improved potency, and then synthetic truncated peptides were used to determine a minimum length required for micromolar affinity towards HDM2 of eight amino acids. X-ray crystallographic and NMR spectroscopic data proved indispensable to the further optimization of the 8-mer. Crystallography revealed that a 15-mer p53-derived peptide bound in a deep hydrophobic cleft on HDM2 and adopted a helical conformation. This also identified relevant contacts with the HDM2 protein and residues suitable for structural biasing. This was confirmed further with solution-based studies. A helical conformation was promoted (thus decreasing the entropic cost of binding) by introduction of \(\alpha,\alpha\)-disubstituted amino acids at noncritical residues for interaction with HDM2. A tyrosine residue was also replaced by phosphonomethylphenylalanine to introduce an electrostatic interaction with Lys-94 in HDM2, and substitution on the tryptophan residue was included to better complement a hydrophobic “hole” in the HDM2 protein. These combined modifications resulted in a peptide that inhibited binding of p53 to HDM2-GST with IC\textsubscript{50} = 5 nM for representing a 1700-fold improvement in overall binding affinity.

Many groups have succeeded in developing diverse stabilized helices and helix mimetics to target the interaction between p53 and HDM2, including terphenyl-based helical mimetics by Yin et al. [104], hydrocarbon stabilized helical peptide by Bernal et al. [23], \(\beta\)-hairpin protein epitope mimetics by Fasan et al. [105], helical \(\beta\)-peptide inhibitors by Kritzer et al. [106] and Murray and Gellman [107], and oligobenzamide proteomimetic inhibitors by Plante et al. [108]. Shaginian and coworkers also design an approach utilizing solution-phase synthesis to set up an \(\alpha\)-helix mimetic library for screening of the protein-protein interaction inhibitors [109].

Several miniproteins have been designed to target the interaction between the activation domain of p53 and HDM2, including the superTIP (thioredoxin insert protein) by Böttger et al. [110], and helical scaffolds derived from scorpion toxin and apamin-derived stingins by Lu et al. [111, 112]. Kritzer et al. utilized the “grafting” technology in combination with a functional selection to mature the mini-protein ligands for globular protein receptor rapidly [113].
This group obtained cell permeable β-peptide mimicking p53 activation domain to inhibit the p53/HDM2 complex formation [114].

A further example of the enhanced biological effects that constrained peptides exert upon their targets involves peptide inhibitors of the envelope glycoprotein of HIV-1 (gp41), which mediates membrane fusion between the virus and target cells. This hexameric domain contains an N-terminal glycine-rich fusion sequence and two helical regions containing hydrophobic 4-3 heptad repeats denoted as N- and C-helical regions. The N-terminal portion forms a parallel trimer, and the C-terminal portion surrounds this inner core as indicated by X-ray crystallography (Figure 9) [115, 116]. Upon binding cell surface receptor, gp41 undergoes a conformational change that exposes the hydrophobic N-helical regions and allows the fusion peptides to insert into the host cell membrane. Inhibitors of HIV-1 entry into host cells could be envisioned by binding the N-terminal core of the coiled coil trimer before the C-terminal peptide binds to form the gp41 fusion protein. The hydrophobic pocket region of HIV-1 gp41 is an attractive target, because it may be less prone to drug-resistant mutations [115, 117–119].

Earlier work has demonstrated that the C-terminal portion of gp41 was a potent inhibitor of viral membrane fusion [120, 121]. Fragments of the C-terminal peptide of gp41 (residues 643–678) were designed to contain covalent diaminoalkyl tethers between glutamate i, i + 7 residues. Peptides having one or two covalent tethers were shown to be significantly α-helical from 7°C to 37°C by circular dichroism. ELISA quantified the inhibition of viral infectivity from the amount of p24 antigen (from cell lysates) found in cells treated with either free HIV virus or HIV virus particles incubated with inhibitor peptides bearing one or two cross-linked glutamines. Peptides that were cross-linked on the face of the peptide proposed to bind the core trimer were inactive, whilst peptides with two cross-links were more effective than those with one. Though in these studies, short C-peptides corresponding to the pocket-binding region failed to inhibit HIV-1 entry, most likely due to weak binding to the target.

A group from Genentech reported inhibition of HIV-1 infectivity by constrained α-helical peptides [122]. Because short peptides generally do not form stable α-helices in solution, a covalent crosslink was used to link the i and i + 7 amino acid residues and forced the peptide to adopt the helical presentation. The induced helicity was confirmed by CD analysis. HIV 24, HIV 30, and HIV 31 showed characteristic CD pattern of α-helices, while unconstrained peptide HIV 35 has an almost featureless spectrum. Then the constrained peptides were tested in viral infectivity assays. HIV35, in which the C-terminus of DP178 was chopped, showed a dramatic drop in activity compared to the full length of the helical region of gp41. The singly constrained peptide, HIV 24, partially restored the activity. By contrast, the doubly constrained peptide showed comparable affinity to DP178, suggesting a correlation between helicity and inhibitory potency. The lack of inhibition by HIV30 showed the exposed face of the helix was required.

Sia and coworkers have also shown that constrained C-peptides disrupt the assembly of the hexameric gp41 core that leads to HIV-1 viral fusion with host cells [123]. The two strategies that were employed to stabilize the helix are (1) the use of unnatural helix-favoring amino acids and (2) covalent cross-linkers. α-Aminoisobutyric acid (Aib) was a well-studied unnatural amino acid that contains two methyl groups attached to the a carbon and its α,α-disubstituted structure restricts its conformation to 3_10 helices so substitution of Aib into a peptide sequence can dramatically increase its helical propensity. As an alternative helix-stabilizing strategy, α,ω-diaminoalkane was used to connect two glutamic acid residues at i, i + 7 positions in order to induce the helicity. Both of strategies succeeded in promoting the inhibitory activities of a C14 peptide that targets the HIV-1 gp41 hydrophobic pocket. C14Aib and C14linkmid, respectively, showed 144 μM and 35 μM IC50 in
the third lactam constraint. Their binding assay which used the recombinant hPTH/hPTHrP receptor showed the tricyclopeptide 5 could reach the similar potency with peptide 4 at the low nanomolar level [125]. Peggion and coworkers used to take another strategy to stabilize the helices of bovine parathyroid hormone [126]. Ca-tetrasubstituted amino acids were used to induce the formation of 3_{10} helices. Structure-function relationships were studied with several analogues with an introduced Aib residue at the positions 12 and 13 (Table 1). It was observed that the analogue 7 has the best affinity with an EC_{50} of 0.2 nM.

Most recently, another example to use Aib constraint in the designed peptide to induce helical conformation was presented by Das et al. lately [127]. The α-aminoisobutyric acid-(Aib-) rich peptides were well documented to form 3_{10} helices due to the steric strain on the Ca-position. The targeted 3_{10} helices regions are in general shorter than the α-helices so they made the constrained peptide a very attractive strategy to adopt the secondary conformation [128]. In the approach to inhibit γ-secretase, which is a critical player in the process of development of Alzheimer’s disease, Wolfe and coworkers designed short peptides sequence ranging from six to ten residues (two or three of them are Aib residues) based on the helical region APP transmembrane domain. CD experiments were conducted to study the conformation, and characteristic spectra were observed. Though further clarification of the helical conformation was not shown, presumably because the spectroscopic differentiation of the 3_{10}-helix from α-helices is traditionally difficult. Nonetheless, low micromolar level IC_{50} was observed in the purified enzyme assay. Further information provided that the adopted conformation played an important role in the inhibition, and partial inversion of the α-stereocenters led to a 100-fold loss of potency, suggesting that the helical conformation rather than hydrophobicity is critical in the inhibition of γ-secretase.

Schepartz’s group developed a general solution called “protein grafting,” which, often used in combination with molecular evolution, identified miniature protein with high affinity and specificity for proteinaceous and nucleic acid targets [129–133]. A recent application of this approach is the identification of the high-affinity ligands for the CBP KIX domain [134]. The complex between the KIX domain of the transcriptional coactivator protein (CREB binding protein, CBP) and the kinase-inducible activation domain (KID) of the transcription factor CREB is a challenging target to recognize as the KID-binding cleft on the surface of KIX is shallow and more resembles the solvent-exposed protein surface than a typical α-helical-binding groove [135]. Hydrophobic interaction contributes significantly to the free energy of KID^α - KIX complex formation: the side chains at i, i + 3, i + 4, i + 7 positions (Try134, Ile137, Leu138, Leu141) on the same face of the helical region of CREB KID are interacting with the surface of KIX. These residues are grafted onto the solvent-exposed α-helical face of the small yet stable protein avian pancreatic polypeptide (aPP) [136, 137]. The resulted phosphopeptide PPKID^4, with the additional functional epitope (GPSQPTYFGDDAPVRLSFFYILLDLYLDAPGVC) to

![Figure 10: A surface model of the trimeric coiled coil. The interacting side chains at i, i + 3, i + 7 positions of C14 peptide are shown in green.](image-url)
recognize CBP KIX surface on its desired secondary conformations, exhibited high affinity ($K_i = 562 \pm 41 \text{nM}$) and high selectivity over carbonic anhydrase ($K_i/CA = 106 \pm 12 \mu\text{M}$) and calmodulin ($K_i/CalM = 52 \pm 12 \mu\text{M}$) that also bind hydrophobic or $\alpha$-helical ligands [4, 138, 139]. It is particularly noteworthy that the grafted miniature protein showed high preference (100-fold) to recognize CBP KIX over calmodulin, whose native ligand smooth muscle myosin light-chain kinase (smMLCK) also adopts an $\alpha$-helical conformation with the key binding residues at $i, i+3$, $i+7$ positions (Trp800, Thr803, and Val807) [139], indicating the “protein grafting” is a sensitive method to identify inhibitors of protein–protein interactions while further structural affirmation of the inhibition mode is desirable.

Ellman and coworkers developed a general method to prepare constrained peptidyl mimetics of $\beta$-turn based on solid-phase synthesis with a variety of side chains functionality at the $i+1$, $i+2$, and $i+3$ positions incorporated [73, 74]. As an application of this design, a library of 2302 small molecule $\beta$-turn mimetics generated from the solid-phase synthesis was screened for inhibition of $\alpha\beta1$ intertretin-CS1 splice variant binding interaction [140]. Active compounds were identified with the best lead (Figure 11(a)) with an IC$_{50}$ of 5 $\mu$M. In another search of potential to target human somatostatin receptors (hSST), a focused library of $\beta$-turn mimetics based upon the crucial Trp-Lys motif found in the turn region of somatostatin was screened and resulted in the identification of a potent heterocyclic ligand (Figure 11(b)) with an IC$_{50}$ value of 87 nM against subtype 5 human somatostatin receptor (hSST5) [141]. With the aid of the vector search program CAVEAT [142], Etzkorn and coworkers designed a chimeric cyclic peptide (Figure 11(b)) to structurally mimic a $\beta$-turn region of tendamistat, which is a 74-residue protease-inhibitory inhibitor of $\alpha$-amylase (Figure 11(c)) [143]. The targeted area of tendamistat is the $^{19}$Trp$^{19}$Arg$^{19}$Tyr residues that occupy the $i+1$ to $i+3$ positions of a slightly distorted type I $\beta$-turn, with the $^{19}$Arg side chain sandwiched between the adjacent aromatic rings. In order to evaluate the abilities of the chimeric peptides to inhibit $\alpha$-amylase, an assay was developed on the basis of the hydrolysis of $p$-nitrophenyl maltooligoside ($p$-NPG3).

Table 1: Sequences of constrained human parathyroid hormone peptides.

| Peptide | EC$_{50}$ (nM) |
|---------|---------------|
| hPTH-(1-31)NH$_2$ (1) | 19.9 |
| [Leu$^{27}$]cyclo(Glu$^{25}$-Lys$^{6}$)-hPTH-(1-31)-NH$_2$ (2) | 3.3 |
| cyclo(Lys$^{18}$-Asp$^{23}$)[Ala$^{1}$, Nle$^{8}$, Lys$^{18}$, Asp$^{23}$, Leu$^{27}$]hPTH(1-31)NH$_2$ (3) | 0.29 |
| bicyclo(Lys$^{18}$-Asp$^{23}$, Lys$^{26}$-Asp$^{30}$)[Ala$^{1}$, Nle$^{8}$, Lys$^{18}$, Asp$^{23}$, Leu$^{27}$]hPTH(1-31)NH$_2$ (4) | 0.13 |
| tricyclo(Lys$^{13}$, Asp$^{17}$, Lys$^{18}$-Asp$^{22}$, Lys$^{26}$-Asp$^{30}$)[Ala$^{1}$, Nle$^{8}$, Lys$^{18}$, Asp$^{17}$, Asp$^{22}$, Leu$^{27}$]hPTH(1-31)NH$_2$ (5) | 0.14 |
| [Nle$^{8}$, Nal$^{13}$, Tyr$^{14}$]bPTH(1-34)-NH$_2$ (6) | 0.85 |
| [Nle$^{8}$, Nal$^{13}$, Tyr$^{14}$]bPTH(1-34)-NH$_2$ (7) | 0.2 |

| Peptide | EC$_{50}$ (nM) |
|---------|---------------|

4. Conclusions

In this paper, we have highlighted the progress made in the stabilization of protein secondary structures. These peptidomimetics render novel strategies to disrupt therapeutically important protein–protein interactions such as the gp41 complex formation, the p53-HDM2 interactions, and embryonic development. Recent work of Henchey et al. demonstrated that HBS helices mimicking a helical segment in the C-terminal activation domain of hypoxia-inducible transcription factor (HIF)-1$\alpha$ can bind to the cysteine-histidine rich 1 (CH1) region of CBP/p300 and inhibit transcription of hypoxia-inducible genes in cell culture [30]. Hypoxia-inducible genes encode vascular endothelial growth factor (VEGF) and its receptor VEGF$\alpha$ involved in the induction of solid tumors angiogenesis (growth of new blood vessels) [144]. The ligands inhibiting hypoxia-inducible gene expression may be designed for the treatment of neovascularization in solid tumors.
Bcl-Bak family proteins that play important roles in apoptosis. Constrained peptides, as miniature protein mimetics, present the essential recognition functionality of secondary structures involved in protein–protein interactions, providing a generally applicable method to target the “undruggable” protein-protein interactions. It is also possible to move beyond secondary structure and disrupt protein-protein interactions mediated by interfacial contact of large surface areas.

References

[1] F. Ruan, Y. Chen, and P. B. Hopkins, “Metal ion enhanced helicity in synthetic peptides containing unnatural, metal-ligating residues,” Journal of the American Chemical Society, vol. 112, no. 25, pp. 9403–9404, 1990.

[2] J. M. Adams and S. Cory, “The Bcl-2 protein family: arbiters of cell survival,” Science, vol. 281, no. 5381, pp. 1322–1326, 1998.

[3] P. H. Kussie, S. Gorina, V. Marechal et al., “Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain,” Science, vol. 274, no. 5289, pp. 948–953, 1996.

[4] B. P. Orner, J. T. Ernst, and A. D. Hamilton, “Toward proteinomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an α-helix,” Journal of the American Chemical Society, vol. 123, no. 22, pp. 5382–5383, 2001.

[5] B. Aghazadeh, W. E. Lowry, X. Y. Huang, and M. K. Rosen, “Structural basis for relief of autoinhibition of the Dbll homology domain of proto-oncogene Vav by tyrosine phosphorylation,” Cell, vol. 102, no. 5, pp. 625–633, 2000.

[6] L. Pauling and R. B. Corey, “The configuration of polypeptide chains in proteins,” Fortschrritte Der Chemie Organischer Naturstoffe, vol. 11, pp. 180–239, 1954.

[7] L. Regan, “What determines where α-helices begin and end?” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 23, pp. 10907–10908, 1993.

[8] E. Galoppini and M. A. Fox, “Effect of the electric field generated by the helix dipole on photoinduced intramolecular electron transfer in dichromophoric α-helical peptides,” Journal of the American Chemical Society, vol. 118, no. 9, pp. 2299–2300, 1996.

[9] J. Martin Scholtz, E. J. York, J. M. Stewart, and R. L. Baldwin, “A neutral, water-soluble, α-helical peptide: the effect of ionic strength on the helix-coil equilibrium,” Journal of the American Chemical Society, vol. 113, no. 13, pp. 5102–5104, 1991.

[10] D. P. Fairlie, M. L. West, and A. K. Wong, “Towards protein surface mimetics,” Current Medicinal Chemistry, vol. 5, no. 1, pp. 29–62, 1998.

[11] M. J. I. Andrews and A. B. Tabor, “Forming stable helical peptides using natural and artificial amino acids,” Tetrahedron, vol. 55, no. 40, pp. 11711–11743, 1999.

[12] D. Y. Jackson, D. S. King, J. Chmielewski, S. Singh, and P. G. Schultz, “General approach to the synthesis of short α-helical peptides,” Journal of the American Chemical Society, vol. 113, no. 24, pp. 9391–9392, 1991.

[13] C. Yu and J. W. Taylor, “Synthesis and study of peptides with semirigid i and i+7 side-chain bridges designed for α-helix stabilization,” Bioorganic and Medicinal Chemistry, vol. 7, no. 1, pp. 161–175, 1999.

[14] G. Ösapay and J. W. Taylor, “Multicyclic polypeptide model compounds. 2. Synthesis and conformational properties of a highly α-helical uncospapeptide constrained by three side-chain to side-chain lactam bridges,” Journal of the American Chemical Society, vol. 114, no. 18, pp. 6966–6973, 1992.

[15] A. M. Leduc, J. O. Trent, J. L. Wittliff et al., “Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor—coactivator interactions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11273–11278, 2003.

[16] T. R. Geislinger and R. K. Guy, “Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2,” Journal of the American Chemical Society, vol. 125, no. 23, pp. 6852–6853, 2003.

[17] N. E. Shepherd, H. N. Hoang, V. S. Desai, E. Letouze, P. R. Young, and D. P. Fairlie, “Modular α-helical mimetics with antiviral activity against respiratory syncytial virus,” Journal of the American Chemical Society, vol. 128, no. 40, pp. 13284–13289, 2006.

[18] R. S. Harrison, N. E. Shepherd, H. N. Hoang et al., “Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 26, pp. 11686–11691, 2010.

[19] D. G. Flink, J. R. Kumita, O. S. Smart, and G. A. Woolley, “Using an azobenzene cross-linker to either increase or decrease peptide helix content upon Trans-to-cis photoisomerization,” Chemistry and Biology, vol. 9, no. 3, pp. 391–397, 2002.

[20] H. E. Blackwell and R. H. Grubb, “Highly efficient synthesis of covalently cross-linked peptide helices by ring-closing metathesis,” Angewandte Chemie, vol. 37, no. 23, pp. 3281–3284, 1998.

[21] C. E. Schafmeister, J. Po, and G. L. Verdine, “An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides,” Journal of the American Chemical Society, vol. 122, no. 4, pp. 5891–5892, 2000.

[22] L. D. Walensky, A. L. Kung, I. Escher et al., “Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix,” Science, vol. 305, no. 5689, pp. 1466–1470, 2004.

[23] F. Bernal, A. F. Tyler, S. J. Korsmeyer, L. D. Walensky, and G. L. Verdine, “Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide,” Journal of the American Chemical Society, vol. 129, no. 9, pp. 2456–2457, 2007.

[24] R. E. Moellinger, M. Cornejo, T. N. Davis et al., “Direct inhibition of the NOTCH transcription factor complex,” Nature, vol. 462, no. 7270, pp. 182–188, 2009.

[25] A. Patgiri, A. L. Jochim, and P. S. Arora, “Solid phase synthesis of α helical compounds. 2. Synthesis and conformational properties of a highly α-helical uncospapeptide constrained by three side-chain to side-chain lactam bridges,” Accounts of Chemical Research, vol. 41, no. 10, pp. 1289–1300, 2008.

[26] B. H. Zimm and J. K. Bragg, “Theory of the phase transition between helix and random coil in polypeptide chains,” The Journal of Chemical Physics, vol. 31, no. 2, pp. 526–535, 1959.

[27] S. Lisson and A. Roig, “On the theory of helix-coil transition in polypeptides,” The Journal of Chemical Physics, vol. 34, no. 6, pp. 1963–1974, 1961.

[28] A. Patgiri, M. R. Witten, and P. S. Arora, “Solid phase synthesis of hydrogen bond surrogate derived α-helices: resolving the case of a difficult amide coupling,” Organic and Biomolecular Chemistry, vol. 8, no. 8, pp. 1773–1776, 2010.
interactions,” *Journal of the American Chemical Society*, vol. 123, no. 21, pp. 5162–5163, 2001.

[62] S. H. Gellman, “Foldamers: a Manifesto,” *Accounts of Chemical Research*, vol. 31, no. 4, pp. 173–180, 1998.

[63] C. M. Goodman, S. Cho, S. Shandler, and W. F. DeGrado, “Foldamers as versatile frameworks for the design and evolution of function,” *Nature Chemical Biology*, vol. 3, no. 5, pp. 252–262, 2007.

[64] D. Seebach, D. F. Hook, and A. Glättli, “Helices and other secondary structures of β- and γ-peptides,” *Biopolymers*, vol. 84, no. 1, pp. 23–37, 2006.

[65] D. Seebach and J. Gardiner, “β-Peptidic peptidomimetics,” *Accounts of Chemical Research*, vol. 41, no. 10, pp. 1366–1375, 2008.

[66] W. S. Horne and S. H. Gellman, “Foldamers with heterogeneous backbones,” *Accounts of Chemical Research*, vol. 41, no. 10, pp. 1399–1408, 2008.

[67] J. A. Kritzer, O. M. Stephens, D. A. Guaraccino, S. K. Reznik, and A. Schepartz, “β-Peptides as inhibitors of protein–protein interactions,” *Bioorganic and Medicinal Chemistry*, vol. 13, no. 1, pp. 11–16, 2005.

[68] W. S. Horne, L. M. Johnson, T. J. Ketas et al., “Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 35, pp. 14751–14756, 2009.

[69] D. S. Kemp, I. G. Boyd, and C. C. Muendel, “The helical s constant for alanine in water derived from template-nucleated helices,” *Nature*, vol. 352, no. 6334, pp. 451–454, 1991.

[70] D. S. Kemp, “Efficient helix nucleation by a macrocyclic triproline-derived template,” *Tetrahedron Letters*, vol. 36, no. 23, pp. 4023–4026, 1995.

[71] R. E. Austin, R. A. Maplestone, A. M. Seffler et al., “A template for stabilization of a peptide α-helix: synthesis and evaluation of conformational effects by circular dichroism and NMR,” *Journal of the American Chemical Society*, vol. 119, no. 28, pp. 6461–6472, 1997.

[72] W. M. Kazmierski, R. J. Hazen, A. Aulabaugh, and M. H. StClair, “Inhibitors of human immunodeficiency virus type 1 derived from gp41 transmembrane protein: structure–activity studies,” *Journal of Medicinal Chemistry*, vol. 39, no. 14, pp. 2681–2689, 1996.

[73] A. A. Virgilio and J. A. Ellman, “Simultaneous solid-phase synthesis of β-turn mimetics incorporating side-chain functionality,” *Journal of the American Chemical Society*, vol. 116, no. 25, pp. 11580–11581, 1994.

[74] A. A. Virgilio, S. C. Schürer, and J. A. Ellman, “Expeditious solid-phase synthesis of putative β-turn mimetics incorporating the i + 1, i + 2, and i + 3 sidechains,” *Tetrahedron Letters*, vol. 37, no. 39, pp. 6961–6964, 1996.

[75] K. Burgess, “Solid-phase syntheses of β-turn analogues to mimic or disrupt protein—protein interactions,” *Accounts of Chemical Research*, vol. 34, no. 10, pp. 826–835, 2001.

[76] A. G. Cochran, N. J. Skelton, and M. A. Starovasnik, “Tryptophan zippers: stable, monomeric β-hairpins,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 10, pp. 5578–5583, 2001.

[77] A. G. Cochran, R. T. Tong, M. A. Starovasnik et al., “A minimal peptide scaffold for β-turn display: optimizing a strand position in disulfide-cyclized β-hairpins,” *Journal of the American Chemical Society*, vol. 123, no. 4, pp. 625–632, 2001.

[78] K. Y. Tsang, H. Diaz, N. Graciani, and J. W. Kelly, “Hydroporphic cluster formation is necessary for dibenzofuran-based amino acids to function as β-sheet nucleators,” *Journal of the American Chemical Society*, vol. 116, no. 9, pp. 3988–4005, 1994.

[79] H. Diaz, K. Y. Tsang, D. Choo, J. R. Espina, and J. W. Kelly, “Design, synthesis, and partial characterization of water-soluble β-sheets stabilized by a dibenzofuran-based amino acid,” *Journal of the American Chemical Society*, vol. 115, no. 9, pp. 3790–3791, 1993.

[80] H. Diaz, J. R. Espina, and J. W. Kelly, “A dibenzofuran based amino acid designed to nucleate antiparallel β-sheet structure: evidence for intramolecular hydrogen bond formation,” *Journal of the American Chemical Society*, vol. 114, pp. 8316–8318, 1992.

[81] H. Diaz and J. W. Kelly, “The synthesis of dibenzofuran based dicarboxylic acids and amino acids designed to nucleate parallel and antiparallel β-sheet formation,” *Tetrahedron Letters*, vol. 32, no. 41, pp. 5725–5728, 1991.

[82] R. Kaul, A. R. Angeles, M. Jäger, E. T. Powers, and J. W. Kelly, “Incorporating β-turns and a turn mimetic out of context in loop 1 of the WW domain affords cooperatively folded β-sheets,” *Journal of the American Chemical Society*, vol. 123, no. 22, pp. 5206–5212, 2001.

[83] R. Kaul, S. Deechongkit, and J. W. Kelly, “Synthesis of a negatively charged dibenzofuran-based β-turn mimetic and its incorporation into the WW miniprotein–enhanced solubility without a loss of thermodynamic stability,” *Journal of the American Chemical Society*, vol. 124, no. 40, pp. 11900–11907, 2002.

[84] U. Arnold, M. P. Hindraker, B. L. Nilsson, B. R. Huck, S. H. Gellman, and R. T. Raines, “Protein prosthesis: a semisynthetic enzyme with a β-peptide reverse turn,” *Journal of the American Chemical Society*, vol. 124, no. 29, pp. 8522–8523, 2002.

[85] G. Platt, C. W. Chung, and M. S. Searle, “Design of histidine-Zn2+ binding sites within a β-hairpin peptide: enhancement of β-sheet stability through metal complexation,” *Chemical Communications*, no. 13, pp. 1162–1163, 2001.

[86] S. R. Griffiths-Jones and M. S. Searle, “Structure, folding, and energetics of cooperative interactions between the β-strands of a de Novo designed three-stranded antiparallel β-sheet peptide,” *Journal of the American Chemical Society*, vol. 122, no. 35, pp. 8350–8356, 2000.

[87] G. J. Sharman and M. S. Searle, “Cooperative interaction between the three strands of a designed antiparallel β-sheet,” *Journal of the American Chemical Society*, vol. 120, no. 21, pp. 5291–5300, 1998.

[88] S. H. Gellman, “Minimal model systems for β sheet secondary structure in proteins,” *Current Opinion in Chemical Biology*, vol. 2, no. 6, pp. 717–725, 1998.

[89] H. L. Schenck and S. H. Gellman, “Use of a designed triple-stranded antiparallel β-sheet to probe β-sheet cooperativity in aqueous solution,” *Journal of the American Chemical Society*, vol. 120, no. 19, pp. 4869–4870, 1998.

[90] J. D. Fisk and S. H. Gellman, “A parallel β-sheet model system that folds in water,” *Journal of the American Chemical Society*, vol. 123, no. 2, pp. 343–344, 2001.

[91] J. S. Nowick, E. M. Smith, J. W. Ziller, and A. J. Shaka, “Three-stranded mixed artificial β-sheets,” *Tetrahedron*, vol. 58, no. 4, pp. 727–739, 2002.

[92] J. S. Nowick, D. M. Chung, K. Maitra, S. Maitra, K. D. Stigers, and Y. Sun, “An unnatural amino acid that mimics a tripeptide β-strand and forms β-sheetlike hydrogen-bonded dimers,” *Journal of the American Chemical Society*, vol. 122, no. 32, pp. 7654–7661, 2000.
J. A. Kritzer, J. D. Lear, M. E. Hodsdon, and A. Schepartz,
R. Fasan, R. L. A. Dias, K. Moehle et al., “Using a
J. K. Murray and S. H. Gellman, “Targeting protein-protein
J. P. Plante, T. Burnley, B. Malkova et al., “Oligobenzamide
A. Shaginian, L. R. Whitby, S. Hong et al., “Design, synthesis,
evaluation of an α-helix mimetic library targeting

protein-protein interactions,” Journal of the American Chemical Society, vol. 131, no. 15, pp. 5564–5572, 2009.

A. Böttger, V. Böttger, A. Sparks, W.-L. Liu, S. F. Howard, and D. P. Lane, “Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo,” Current Biology, vol. 7, no. 11, pp. 860–869, 1997.

C. Li, M. Liu, J. Monbo et al., “Turning a scorpion toxin into an antitumor miniprotein,” Journal of the American Chemical Society, vol. 130, no. 41, pp. 13546–13548, 2008.

C. Li, M. Pazgier, M. Liu, W. Y. Lu, and W. Lu, “Apamin as a template for structure-based rational design of potent peptide activators of p53,” Angewandte Chemie, vol. 48, no. 46, pp. 8712–8715, 2009.

J. A. Kritzer, R. Zutshi, M. Cheah et al., “Miniature protein inhibitors of the p53-hDM2 interaction,” ChemBioChem, vol. 7, no. 1, pp. 29–31, 2006.

E. A. Harker and A. Schepartz, “Cell-permeable β-peptide inhibitors of p53/hDM2 complexation,” ChemBioChem, vol. 10, no. 6, pp. 990–993, 2009.

D. C. Chan, D. Fass, J. M. Berger, and P. S. Kim, “Core structure of gp41 from the HIV envelope glycoprotein,” Cell, vol. 89, no. 2, pp. 263–273, 1997.

K. Tan, J. H. Liu, J. H. Wang, S. Shen, and M. Lu, “Atomic structure of a thermostable subdomain of HIV-1 gp41,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 23, pp. 12303–12308, 1997.

D. M. Eckert, V. N. Malashkevich, L. H. Hong, P. A. Carr, and P. S. Kim, “Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket,” Cell, vol. 99, no. 1, pp. 103–115, 1999.

M. Ferrer, T. M. Kapoor, T. Strasmaier et al., “Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements,” Nature Structural Biology, vol. 6, no. 10, pp. 953–960, 1999.

D. C. Chan, C. T. Chutkowski, and P. S. Kim, “Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15613–15617, 1998.

C. T. Wild, D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews, “Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6691–6696, 2003.

S. Jiang, K. Lin, N. Strick, and A. R. Neurath, “HIV-1 inhib-ition by a peptide,” Nature, vol. 365, no. 6442, p. 113, 1993.

J. K. Judice, J. Y. K. Tom, W. Huang et al., “Inhibition of HIV type 1 infectivity by constrained α-helical peptides: implications for the viral fusion mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 25, pp. 13426–13430, 1997.

S. K. Sia, P. A. Carr, A. G. Cochran, V. N. Malashkevich, and P. S. Kim, “Short constrained peptides that inhibit HIV-1 entry,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 11, pp. 4923–4928, 2009.

J. R. Barbier, W. Neugebauer, P. Morley et al., “Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region,” Journal of Medicinal Chemistry, vol. 40, no. 9, pp. 1373–1380, 1997.

S. M. Condon, I. Morize, S. Darnbrough et al., “The bioactive conformation of human parathyroid hormone. Structural
evidence for the extended helix postulate,” *Journal of the American Chemical Society*, vol. 122, no. 13, pp. 3007–3014, 2000.

[126] E. Peggion, S. Mammi, E. Schievano et al., “Structure-function relationship studies of bovine parathyroid hormone [bPTH(1-34)] analogues containing α-amino-iso-butyric acid (Aib) residues,” *Biopolymers*, vol. 68, no. 3, pp. 437–457, 2003.

[127] C. Das, O. Berezovska, T. S. Diehl et al., “Designed helical peptides inhibit an intramembrane protease,” *Journal of the American Chemical Society*, vol. 125, no. 39, pp. 11794–11795, 2003.

[128] I. L. Karle and P. Balaram, “Structural characteristics of α-helical peptide molecules containing Aib residues,” *Biochemistry*, vol. 29, no. 29, pp. 6747–6756, 1990.

[129] J. W. Chin and A. Schepartz, “Design and evolution of a miniature Bcl-2 binding protein,” *Angewandte Chemie*, vol. 40, no. 20, pp. 3806–3809, 2001.

[130] J. W. Chin, R. M. Grotzfeld, M. A. Fabian, and A. Schepartz, “Methodology for optimizing functional miniature proteins based on avian pancreatic polypeptide using phage display,” *Bioorganic and Medicinal Chemistry Letters*, vol. 11, no. 12, pp. 1501–1505, 2001.

[131] J. W. Chin and A. Schepartz, “Concerted evolution of structure and function in a miniature protein,” *Journal of the American Chemical Society*, vol. 123, no. 12, pp. 2929–2930, 2001.

[132] N. J. Zondlo and A. Schepartz, “Highly specific DNA recognition by a designed miniature protein,” *Journal of the American Chemical Society*, vol. 121, no. 29, pp. 6938–6939, 1999.

[133] J. K. Montclare and A. Schepartz, “Miniature homeodomains: high specificity without an N-terminal arm,” *Journal of the American Chemical Society*, vol. 125, no. 12, pp. 3416–3417, 2003.

[134] S. E. Rutledge, H. M. Volkman, and A. Schepartz, “Molecular recognition of protein surfaces: high affinity ligands for the CBP KIX domain,” *Journal of the American Chemical Society*, vol. 125, no. 47, pp. 14336–14347, 2003.

[135] I. Radhakrishnan, G. C. Pérez-Alvarado, D. Parker, H. J. Dyson, M. R. Montminy, and P. E. Wright, “Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator:coactivator interactions,” *Cell*, vol. 91, no. 6, pp. 741–752, 1997.

[136] I. Glover, I. Haneef, and J. Pitts, “Conformational flexibility in a small globular hormone: X-ray analysis of avian pancreatic polypeptide at 0.98-Å resolution,” *Biopolymers*, vol. 22, no. 1, pp. 293–304, 1983.

[137] H. M. Volkman, S. E. Rutledge, and A. Schepartz, “Binding mode and transcriptional activation potential of high affinity ligands for the CBP KIX domain,” *Journal of the American Chemical Society*, vol. 127, no. 13, pp. 4649–4658, 2005.

[138] M. Abul Fazal, B. C. Roy, S. Sun, S. Mallik, and K. R. Rodgers, “Surface recognition of a protein using designed transition metal complexes,” *Journal of the American Chemical Society*, vol. 123, no. 26, pp. 6283–6290, 2001.

[139] W. E. Meador, A. R. Means, and F. A. Quirocho, “Target enzyme recognition by calmodulin: 2.4 Å structure of a calmodulin-peptide complex,” *Science*, vol. 257, no. 5074, pp. 1251–1255, 1992.

[140] A. J. Souers, A. A. Virgilio, S. S. Schürer et al., “Novel inhibitors of α4β1 integrin receptor interactions through library synthesis and screening,” *Bioorganic and Medicinal Chemistry Letters*, vol. 8, no. 17, pp. 2297–2302, 1998.
Submit your manuscripts at http://www.hindawi.com